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Objective: Increasing neutrophil/lymphocyte ratios on preoperative blood tests have been associated with worse
survival after resection of colorectal cancer. We sought to determine factors associated with increasing neutrophil/
lymphocyte ratios and the stage-adjusted prognostic effect in patients undergoing resection for non–small cell
lung cancer.
Methods: We performed a retrospective review of patients undergoing complete resection for non–small cell
lung cancer between 1999 and 2005. Data acquisition was through patient medical records, blood results recorded
on admission before surgical intervention, and follow-up by National Health Service database searches and hos-
pital records. Cox proportional hazards regression was used to estimate the effect of neutrophil/lymphocyte ratio
on stage-adjusted survival.
Results:During the study period, 178 patients underwent pulmonary resection. Of 177 patients, the majority were
male 104 (59%), with a mean age of 63 years (standard deviation, 10 years). The median follow-up time was 29
months (interquartile range, 8–56 months), and overall survival was 83% and 54% at 1 and 5 years, respectively.
Higher stage was the only factor found to be associated with increasing neutrophil/lymphocyte ratios (P¼ .019).
Total white cell count (P¼ .990) and neutrophil count (P ¼ .490), age (P ¼ .290), and cell type (P ¼ .490) were
not significant predictors of mortality. On multivariable analysis after adjusting for stage, increasing neutrophil/
lymphocyte ratios (hazard ratio, 1.10; 95% confidence interval, 1.03–1.17; P ¼ .004) remained an independent
prognostic indicator.
Conclusions: Increasing preoperative neutrophil/lymphocyte ratios are associated with higher stage but remain
an independent predictor of survival after complete resection for primary lung cancer and are a potential
biomarker to stratify high risk of death in patients with stage I disease.Currently, joint guidelines issued by Cancer Care Ontario
and the American Society of Clinical Oncology do not rec-
ommend the use of adjuvant chemotherapy in patients with
completely resected stage I lung cancer.1 Uniformly good
survival in patients with stage I disease is not always the
case because sophisticated, expensive, and not widely avail-
able techniques, such as tumor gene expression profiling, are
able to substratify patients with early-stage cancer into high-
and low-risk subsets.2
The purpose of this study was to determine the factors
associated with increasing neutrophil/lymphocyte ratios
(NLRs) and the relationship to survival in patients with
non–small cell lung cancer to evaluate the discriminating
value of the NLR to stratify patients with stage I disease at
high risk of death.
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The chairman of the ethics committee approved this study and waived
the need for ethics review. This study was conducted on patients operated
on by a single surgeon (PG) between 1999 and 2005 and included all pa-
tients with non–small cell lung cancer who had undergone complete resec-
tion. We excluded any patients with coexistent hematologic disorders or
known active infection at the time of surgical intervention to ensure that
the white cell count was representative of a normal baseline value.
Data Acquisition
Data were compiled from individual patient medical case notes, elec-
tronic patient records (for laboratory results), and pathology reports. Demo-
graphics and serum values for the NLR were measured on the day before the
operation to ascertain the baseline values for neutrophil and lymphocyte
counts. Survival status was determined from the date of last follow-up in
a hospital outpatient clinic or general practitioner clinic. Mortality status
was documented from patient records and the National Health Service
(United Kingdom) strategic tracing service.
Statistical Analysis
Categorical data are presented as frequencies (percentages) and continu-
ous data as means with standard deviations or medians with interquartile
ranges. Regression analysis was used to ascertain factors associated with in-
creasing NLRs, and logarithmic transformation of the NLR was required to
satisfy distributional assumption required for linear regression.
Receiver operating characteristic plots were constructed in the stage I
subset of patients to determine the joint maximum sensitivity and specificity
of a threshold value to stratify patients at high risk of death.
Actuarial survival was estimated by using the Kaplan–Meier method,
and differences were tested with the log-rank test. Increasing values ofardiovascular Surgery c Volume 137, Number 2 425




NLR ¼ neutrophil/lymphocyte ratio
NLR were expressed in tertiles to retain sufficient numbers per group for
comparison. Cox proportional hazards regression was used to ascertain
the individual contribution of factors associated with survival and to com-
pare the stage-adjusted survival. Statistical analyses were performed with
Stata version 9.2 (StataCorp, College Station, Texas) and R version 2.4.1
(R Core Development Team, Vienna, Austria).3
RESULTS
From January 1, 1999, to December 31, 2005, a total of
178 patients underwent surgical resection for non–small
cell lung cancer. We excluded 1 patient with leukemia,
leaving 177 suitable for inclusion. Systematic nodal dissec-
tion was undertaken in all cases. The mean age of the cohort
was 63 years (standard deviation, 10 years), and 104 (59%)
were men. The baseline characteristics, extent of operation,
and pathologic stage are presented in Table 1. Follow-up
was complete, with a median time to follow-up of 29 months
(interquartile range, 8–56 months) and a 1- and 5-year over-
all survival of 83% and 54%, respectively.
Determinants of Increasing NLR Status
On regression analysis, neither age (P ¼ .259), sex (P ¼
.786), nor smoking were associated with increasing NLRs.
Increasing overall pathologic stage (P ¼ .019), as assessed
by means of likelihood ratio testing, was the only variable
identified to be associated with increasing NLRs.
Predictors of Survival
On univariable Cox regression modeling, neither total
white cell count (P ¼ .990) nor neutrophil count (P ¼
.490) was significantly associated with risk of death. Increas-
ing lymphocyte count was observed to be associated with
a lower hazard ratio for death at 0.62 (P¼ .012), and increas-
ing NLRs were observed to be associated with an increasing
hazard ratio of death at 1.10 (P ¼ .001, Figure 1). Hazard
ratios of the covariates explored on univariable analysis
are presented in Table 2.
On multivariable modeling, increasing NLRs were inde-
pendent of pathologic stage (Table 3). The joint estimate
of the effect per single unit increase in NLR after adjusting
for pathologic stage was a hazard ratio of 1.10 (95% CI,
1.03–1.17; P ¼ .005).
Discrimination in Stage I Survival
In the 83 patients with stage I disease, an NLR value of
3.81 corresponded to the maximum joint sensitivity and
specificity on the receiver operating characteristic plot.
When applied to a Kaplan–Meier model, a clear distinction
in survival was obtained (P< .001, Figure 2).426 The Journal of Thoracic and Cardiovascular SurDISCUSSION
The results of our study suggest that increasing NLRs are
associated with increasing tumor stage but exert an indepen-
dent effect on survival in patients with completely resected
non–small cell lung cancer, even after adjustment for stage.
The NLR, an inexpensive, reproducible, and widely avail-
able blood test, has been found to be an important indicator
of adverse prognosis in colorectal4,5 and gastric6 cancers.
Although the cause for the association between increasing
NLRs and adverse outcome has not been elucidated, individ-
ually, a high neutrophil count has been reported as an
adverse marker of prognosis in metastatic melanoma7 and
renal cell carcinoma,8 and a low lymphocyte count has
been reported as a marker of mortality in pancreatic cancer.9
Recently, an increasing neutrophil count has also been
identified as an independent predictor of death in patients
with advanced non–small cell lung cancer,10 and neutrophils
have been implicated in the promotion of aerogenous metas-
tasis in patients with bronchioloalveolar carcinoma.11 On its
own, as an isolated measured variable, we did not find any
TABLE 1. Baseline characteristics, operation extent, and stage
Total
No. 177
Age, y (SD) 63 (10)
Male, n (%) 104 (59)
Right-sided resection, n (%) 95 (54)
Mean white cell count, 3 109 (SD) 9.16 (3.92)
Mean neutrophil count, 3 109 (SD) 6.32 (3.61)
Mean lymphocyte count, 3 109 (SD) 1.95 (0.79)
Median neutrophil/lymphocyte ratio (IQR) 3.13 (2.08–4.36)
Operation
Pneumonectomy, n (%) 31 (18)
Lobectomy, n (%) 128 (72)
Bilobectomy, n (%) 14 (8)
Segmentectomy, n (%) 4 (2)
Histology
Squamous, n (%) 56 (32)
Adenocarcinoma, n (%) 86 (49)
Large cell, n (%) 16 (9)
Mixed, n (%) 5 (3)
Other, n (%) 14 (8)
Pathologic stage
IA, n (%) 25 (14)
IB, n (%) 58 (33)
IIA, n (%) 7 (4)
IIB, n (%) 38 (21)
T2 N1 28 (16)
T3 N0 10 (6)
IIIA, n (%) 38 (21)
T1-3 N2 33 (19)
T3 N1 5 (3)
IIIB, n (%) 7 (4)
T4 7 (4)
IV, n (%) 4 (2)
SD, Standard deviation; IQR, interquartile range.gery c February 2009
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Sassociation between the absolute value of the neutrophil
count on survival after complete resection of early-stage
non–small cell lung cancer; in part this might be due to statis-
tical variation or simply the lack of a consistent relationship.
A low lymphocyte count is a recognized predictor of poor
survival in patients with advanced cancer attributed to the
fundamental role of lymphocytes in cell-mediated immunity
with destruction of host cancer cells and has been found to be
a predictive marker of response to chemotherapy.12 Our re-
sults are consistent in this cohort of patients with early-stage
lung cancer, even after complete resection, because higher
preoperative lymphocyte counts were found to be associated
with improved survival. It is plausible that host cell-medi-


























FIGURE 1. Survival by neutrophil/lymphocyte ratio tertiles.
TABLE 2. Univariable predictors of survival
Covariate Hazard ratio 95% CI P value
Neutrophil count, 3 109 mL* 1.02 0.96–1.09 .490
Lymphocyte count, 3 109 mL* 0.62 0.43–0.90 .012
Total white cell count, 3 109 mL* 1.00 0.94–1.07 .990
Neutrophil/lymphocyte ratio* 1.10 1.04–1.17 .001
N category
N0 1.00 NA NA
N1 2.06 1.13–3.74 .018
N2 1.99 1.09–3.62 .024
Stage
I 1.00 NA NA
II 1.59 0.84–3.03 .160
III 2.17 1.22–3.86 .009
IV 1.99 0.47–8.42 .350
Age (per additional year) 1.01 0.99–1.04 .290
Female sex 1.56 0.93–2.61 .089
CI, Confidence interval; NA, not applicable. *Per unit increase.The Journal of Thoracic and Cated immunity continues to exert important effects on de-
struction of any residual tumor cells and micrometastases,
despite complete resection of the main tumor. It will require
a study of relapse patterns to assess the possible implications
and mechanisms of NLRs.
In small cell lung carcinoma, after complete resection,
high lymphocyte counts have been associated with improved
survival, which is ascribed to the pivotal role of specific
T-cell subsets (including tumor-infiltrating lymphocytes) in
cytotoxic cell death and cytokine production that regulates
proliferation and metastatic activity of tumor cells.13
The NLR, as a measure of the relative differences of the
baseline neutrophil and lymphocyte counts, was discovered
to be a more powerful predictor of death than either compo-
nent alone or pathologic stage. On regression analysis, we
demonstrated the association between stage and increased
NLR (P ¼ .019). However, it is not possible to distinguish
cause from effect, increasing tumor burden might incite
a neutrophil reaction, and certainly an association was also
present between increasing absolute neutrophil counts and
increasing pathologic stage (P ¼ .017). Multivariable mod-
eling, however, confirmed a more independent (and more
powerful) effect than pathologic stage as a biomarker of
poor prognosis. This has also been recently reported in ad-
vanced lung cancer, where a similar association was
TABLE 3. Multivariable predictors of survival
Covariate Hazard ratio 95% CI P value
Neutrophil/lymphocyte ratio* 1.10 1.03–1.17 .005
Stage (.126)y
I 1.00 NA NA
II 1.23 0.62–2.45 .550
III 2.03 1.14–3.62 .017
IV 1.64 0.39–7.01 .500
CI, Confidence interval; NA, not applicable. *Per unit increase. yThe overall contribu-
tion of stage was assessed by using the likelihood method.
FIGURE 2. Survival of 83 patients with pathologic stage I disease. NLR,
Neutrophil/lymphocyte ratio; ROC, receiver operating characteristic.ardiovascular Surgery c Volume 137, Number 2 427
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phocyte/neutrophil ratio), and lower scores were identified
as an increasing independent predictor of death.14
Currently, joint guidelines issued by Cancer Care Ontario
and the American Society of Clinical Oncology do not rec-
ommend the use of adjuvant chemotherapy in patients with
completely resected stage I lung cancer,1 citing little evi-
dence of efficacy in these subgroups. The NLR is a potential
biomarker to influence patient selection in this regard be-
cause it is almost universally available and adds no addi-
tional cost to routine preoperative workup in comparison
with more sophisticated and expensive technologies.2
Clearly further validation work and a feasibility study are re-
quired before it can be considered for clinical use.
CONCLUSIONS
Increasing preoperative NLRs are associated with higher
stage but remain an independent predictor of survival after
complete resection for non–small cell lung cancer and are
a potential biomarker to stratify high risk of death in patients
with stage I disease.
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